NCT03517137

Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2019-08-01Est. Completion: 2023-08-28

Enrollment target: 150 participants

Locations

ZNA Stuivenberg, Antwerp, Belgium
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
U.Z. Leuven - Campus Gasthuisberg, Leuven, Belgium
University Hospitals Copenhagen - Rigshospitalet, Copenhagen, Denmark
Amsterdam UMC - Locatie AMC, Amsterdam, Netherlands
Deventer Ziekenhuis, Deventer, Netherlands
University Medical Center Groningen, Groningen, Netherlands
Medisch Centrum Leeuwarden-Zuid, Leeuwarden, Netherlands
Haaglanden Medisch Centrum (HMC) - Haaglanden MC - locatie Antoniushove, Leidschendam, Netherlands
Radboudumc - Radboud University Medical Center Nijmegen, Nijmegen, Netherlands
Erasmus MC, Rotterdam, Netherlands
Maria Sklodowska Curie National Institute of Oncology - National Research Institute, Warsaw, Poland
Instituto Portugues De Oncologia - Francisco Gentil - Centro De Lisboa, Lisbon, Portugal
National Cancer Institute, Bratislava, Slovakia
Hospital Duran i Reynals (Institut Catala D'Oncologia), L'Hospitalet de Llobregat, Spain
Complejo Hospitalario de Navarra, Pamplona, Spain

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRecurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic Leukemia

This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating p…

Birmingham, United StatesEst. completion Feb 1, 2027

Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-ac…

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.